Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-Angiogenic Chemotherapy in Relapsed or Progressive Cancer
NCT00165451Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2001
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide, celecoxib oral solution, etoposide, cyclophosphamide in cancer, sponsored by Dana-Farber Cancer Institute. Started Jun 2001; status: completed.
02
Drugs
thalidomidecelecoxib oral solutionetoposidecyclophosphamide
03
Conditions
cancer
Beyond the preview
Go deeper on NCT00165451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00165451.